[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.19.31. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
Practice Gaps
October 2013

Evaluating the Clinical Utility of Autoantibodies in Morphea

Author Affiliations
  • 1Division of Pediatric Dermatology, Department of Dermatology, Medical College of Wisconsin, Milwaukee
JAMA Dermatol. 2013;149(10):1166. doi:10.1001/jamadermatol.2013.4908

Morphea is an insidious disease with an unpredictable course and wide spectrum of clinical manifestations ranging from skin-limited plaques to linear morphea involving muscle or bone. There can be morbidity from cosmetic disfigurement, functional limb defects, or internal organ involvement. Studies have demonstrated the efficacy of methotrexate or UV-A1 phototherapy for severe disease; however, even after treatment or spontaneous remission, scars and other permanent disease sequelae remain.

First Page Preview View Large
First page PDF preview
First page PDF preview
×